Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;57(7):792-799.
doi: 10.1111/apt.17352. Epub 2022 Dec 28.

Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors

Franck Carbonnel  1   2   3 , Emilie Routier  4 , Thierry Lazure  5 , Charlotte Mussini  5 , Christophe Bellanger  1 , Carine Merklen  6 , Bakhtiar Bejou  7 , Anthony Buisson  8 , Aurélien Amiot  1   2   3 , Antoine Meyer  1   2   3 , Catherine Dong  1   2   3 , Caroline Robert  2   4
Affiliations

Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors

Franck Carbonnel et al. Aliment Pharmacol Ther. 2023 Apr.

Abstract

Background and aims: Dual blockade of BRAF and MEK kinases is a standard of care for metastatic V600E/K BRAF mutant melanoma. This study reports the first systematic description of colitis due to BRAF and MEK inhibitors.

Methods: We studied consecutive patients with melanoma, treated with BRAF and MEK inhibitors, who had colitis requiring hospitalisation. Electronic files were studied; endoscopic biopsies and colectomy specimens were read centrally.

Results: Between January 2021 and March 2022, nine women and one man, aged 50-90 years, were studied. Nine patients received encorafenib and binimetinib; one patient received dabrafenib and trametinib. The main symptoms were diarrhoea, haematochezia, abdominal pain and intestinal obstruction. Blood tests showed anaemia, increased CRP and low serum albumin levels in most patients. All patients had ulcerations of the right colon with (2/10) or without (8/10) stenosis of the ileocecal valve, and 4/10 patients also had ulcerations distal to the right colon. Histopathological findings were suggestive of ischaemia and mild inflammation. Nine of the 10 patients discontinued BRAF/MEK inhibitors. Drugs were reintroduced in four patients, three of whom had a severe relapse of diarrhoea. Two patients required surgery and underwent intestinal resection. One patient died of enterocolitis.

Conclusion: BRAF/MEK inhibitors can induce severe colitis characterised by ulcerations of the right colon.

Keywords: BRAF/MEK inhibitor; colitis; melanoma.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Hamdeh S, Micic D, Hanauer S. Drug-induced colitis. Clin Gastroenterol Hepatol. 2021;19:1759-79.
    1. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-26.
    1. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006-17.
    1. Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, et al. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut. 2018;67:2056-67.
    1. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, de Giorgi V, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30:2522-9.

MeSH terms

Substances